{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pumitamig (BNT327)","carboplatin","etoposide"],["pumitamig (BNT327)","paclitaxel"],["pumitamig (BNT327)","topotecan"]],"indication":"untreated extensive-stage or previously treated small-cell lung cancer","name":"BNT327-01","nct_id":"NCT06449209","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bnt327-01-nct06449209. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting","label":"Cohort 1 Arm 1 - BNT327 DL1 + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":"Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting","label":"Cohort 1 Arm 2 - BNT327 DL2 + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":"Participants with SCLC who have disease progression/relapse","label":"Cohort 2 Arm 1 - BNT327 DL1 + paclitaxel","type":"EXPERIMENTAL"},{"description":"Participants with SCLC who have disease progression/relapse","label":"Cohort 2 Arm 2 - BNT327 DL2 + paclitaxel","type":"EXPERIMENTAL"},{"description":"Participants with SCLC who have disease progression/relapse","label":"Cohort 3 Arm 1 - BNT327 DL1 + topotecan","type":"EXPERIMENTAL"},{"description":"Participants with SCLC who have disease progression/relapse","label":"Cohort 3 Arm 2 - BNT327 DL2 + topotecan","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-02","type":"ESTIMATED"},"conditions":["Extensive-stage Small-cell Lung Cancer","Small-cell Lung Cancer"],"enrollment":{"count":110,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BNT327 Dose Level 1 (DL1)","otherNames":[],"type":"DRUG"},{"name":"BNT327 Dose Level 2 (DL2)","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-06","lead_sponsor":"BioNTech SE","official_title":"A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs","timeFrame":"up to 100 days after the last dose of treatment"},{"measure":"Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs","timeFrame":"up to 100 days after the last dose of treatment"},{"measure":"Objective Response Rate","timeFrame":"until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment"},{"measure":"Best percentage change from baseline in the tumor size","timeFrame":"Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment"},{"measure":"Proportion of participants who have achieved early tumor shrinkage","timeFrame":"up to 2 months after first dose of treatment"}],"references":[],"start_date":{"date":"2024-08-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","url":"https://clinicaltrials.gov/study/NCT06449209"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bnt327-01-nct06449209"}